Jennifer Taubert is Company Group Chairman, Johnson & Johnson, where she is responsible for the Janssen Pharmaceutical Companies throughout North America and Latin America. She is a member of the Corporation’s Management Committee and the Pharmaceuticals Group Operating Committee.
Jennifer has been a leader in shaping Janssen’s global strategy of transformational medical innovation, successfully commercializing critical new medicines that significantly improve the lives of patients living with cancer, immune-related diseases, heart disease and diabetes, infectious diseases including HIV, pulmonary hypertension and serious mental illness. She has built a portfolio that includes nine blockbuster therapies, and under her leadership Janssen has become one of the largest and fastest-growing pharmaceutical companies and a major catalyst of Johnson & Johnson’s growth. Jennifer is also recognized as a champion of diversity and inclusion, which she sees as critical to insight, innovation and business success.
In 2005, Jennifer joined Johnson & Johnson to lead global commercial strategy for Internal Medicine and Early Development for the Pharmaceuticals Group. Later, as President, Internal Medicine, she built a powerhouse new franchise in the cardiovascular and metabolism space, where Janssen is now a leader in both anticoagulation and diabetes. Prior to joining Johnson & Johnson, Jennifer spent 18 years in positions of increasing scope and responsibility at Merck and Allergan.
Jennifer was named to Fortune magazine’s “Most Powerful Women” list in 2016 and 2017, and received the National Association for Female Executives’ 2017 “Woman of Achievement” award. In addition to her leadership at Johnson & Johnson, Jennifer represents Johnson & Johnson on the Board of Directors of the Biotechnology Innovation Organization (BIO), the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations. She is also a member of the National Academy of Medicine Leadership Consortium for Value and Science-Driven Healthcare, and at the global level, Jennifer represents Johnson & Johnson on the Executive Committee of the International Section of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Jennifer received a Bachelor’s degree in Pharmacology from the University of California, Santa Barbara and a Master’s of Business Administration from the Anderson Graduate School of Management, University of California, Los Angeles.